Jim Simons Cel Sci Corp Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Cel Sci Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 173,800 shares of CVM stock, worth $154,682. This represents 0.0% of its overall portfolio holdings.

Number of Shares

173,800

Previous 133,800 29.9%

Holding current value

$154,682

Previous $256,000 21.48%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$1.11 - $1.85 $44,400 - $74,000	40,000 Added 29.9%	173,800 $201,000
Q1 2024 May 13, 2024	BUY	$1.63 - $3.08 $153,383 - $289,828	94,100 Added 237.03%	133,800 $256,000
Q4 2023 Feb 13, 2024	BUY	$1.07 - $3.07 $42,479 - $121,879	39,700 New	39,700 $108,000
Q4 2022 Feb 13, 2023	BUY	$1.99 - $3.52 $21,575 - $38,163	10,842 Added 82.24%	24,025 $56,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $635,613 - $1.08 Million	-205,700 Reduced 93.98%	13,183 $41,000
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $1.43 Million - $2.76 Million	-554,000 Reduced 71.68%	218,883 $985,000
Q1 2022 May 13, 2022	BUY	$3.93 - $7.7 $3.04 Million - $5.95 Million	772,883 New	772,883 $3.04 Million
Q1 2020 May 14, 2020	SELL	$7.54 - $17.05 $336,155 - $760,140	-44,583 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$6.71 - $9.55 $299,151 - $425,767	44,583 New	44,583 $408,000
Q2 2019 Aug 12, 2019	SELL	$3.77 - $8.67 $669,552 - $1.54 Million	-177,600 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$2.58 - $3.54 $458,208 - $628,704	177,600 New	177,600 $629,000

Others Institutions Holding CVM

# of Institutions

Shares Held

6.21M

Call Options Held

16.6K

Put Options Held

148K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $38.6M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account